

DYNAVAX

Dynavax to Present at the Stifel 2020 Virtual Healthcare Conference

November 2, 2020

EMERYVILLE, Calif., Nov. 2, 2020 /PRNewswire/ -- [Dynavax Technologies Corporation](#) (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that [Ryan Spencer](#), Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, at 3:30 p. m. E.T.



The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event.

About Dynavax

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on [LinkedIn](#).

Contacts:

Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-stifel-2020-virtual-healthcare-conference-301165128.html>

SOURCE Dynavax Technologies